Oral CLADribine in Patients That Change From First-line Disease Modifying Treatments for Multiple Sclerosis: a pROspective effectivenesS and Safety Study (CLAD CROSS)
Latest Information Update: 22 May 2024
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLAD CROSS
- Sponsors Merck KGaA
- 11 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2021 New trial record